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Background: The European Randomised Study of Prostate Cancer Screening has shown a 21% relative reduction in prostate
cancer mortality at 13 years. The causes of death can be misattributed, particularly in elderly men with multiple comorbidities, and
therefore accurate assessment of the underlying cause of death is crucial for valid results. To address potential unreliability of end-
point assessment, and its possible impact on mortality results, we analysed the study outcome adjudication data in six countries.
Methods: Latent class statistical models were formulated to compare the accuracy of individual adjudicators, and to assess
whether accuracy differed between the trial arms. We used the model to assess whether correcting for adjudication inaccuracies
might modify the study results.
Results: There was some heterogeneity in adjudication accuracy of causes of death, but no consistent differential accuracy by trial
arm. Correcting the estimated screening effect for misclassification did not alter the estimated mortality effect of screening.
Conclusions: Our findings were consistent with earlier reports on the European screening trial. Observer variation, while
demonstrably present, is unlikely to have materially biased the main study results. A bias in assigning causes of death that might
have explained the mortality reduction by screening can be effectively ruled out.
The European Randomised Study of Prostate Cancer Screening
(ERSPC) is a multi-centre trial, which has been conducted in seven
European countries since the early 1990s, with the objective of
estimating the reduction in prostate cancer mortality that might be
achievable by PSA-based screening (Schro¨der et al, 2009, 2012,
2014). Approximately 160 000 men aged 55–69 years at entry were
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randomised to a screening or a control arm and after 13 years of
follow-up, a 21% reduction in prostate cancer mortality has been
demonstrated.
In contrast, the Prostate Lung Colorectal and Ovary (PLCO)
trial conducted in the United States, with approximately 77 000
men, failed to show any mortality benefit (Andriole et al, 2012).
Various explanations have been proposed for the discrepancy of
the findings between these two trials, including higher contamina-
tion in the control arm of the U.S. trial and lower biopsy
compliance following positive screening tests.
Accurate assessment of the underlying cause of death is crucial
for a conclusive evaluation of the effectiveness of prostate cancer
screening, but a major challenge is potential misattribution of the
cause of death particularly in elderly men with multiple
comorbidities (Maudsley and Williams, 1996; Sington and
Cottrell, 2002; Welch and Black, 2010). For prostate cancer,
reasonably high agreement has been reported for official causes of
death compared with judgment based on review of medical records
(Penson et al, 2001; Otto et al, 2003; Fall et al, 2008). Unreliability
in the assessment of the main end point of the screening trials
(prostate cancer mortality) may also influence the results given:
(Schro¨der et al, 2009) that prostate cancer has 5-year survival
commonly around 90% in Western European and North American
countries (Allemani et al, 2015; Schro¨der et al, 2012) that more
men diagnosed with prostate cancer die from other causes than
from prostate cancer (Lu-Yao et al, 2008; Stattin et al, 2010;
Epstein et al, 2012); and that adjudication of the underlying cause
of death is subject to uncertainty (especially among men with
major co-morbidity due to complexity from competing disease
processes that can potentially lead to failure of vital functions and
death) (Kircher et al, 1985; Smith Sehdev and Hutchins, 2001).
Furthermore, it has been suggested that recorded causes of death in
prostate cancer may differ by treatment (Newschaffer et al, 2000).
To assess the level of unreliability of cause of death coding in
ERSPC, and its possible impact on the study results, we analysed
the variation between the adjudicators who had determined the
cause of death for men in the trial, in six out of the seven countries
included in the mortality analyses. We describe the adjudication
protocol for ERSPC, then use data at the level of individual
adjudicators, as well as the overall adjudication committee
consensus on each case. Latent class models (LCMs) were
formulated to assess the accuracy of individual adjudicators, to
determine whether they varied in accuracy, and to assess if their
accuracy might differ between the trial arms. Finally, we used the
modelling results to evaluate whether correcting for variability in
adjudication might substantially modify the main results from
ERSPC, on the association between study arms (screening vs
control) and rates of prostate cancer death.
MATERIALS AND METHODS
Materials. The ERSPC trial protocol has been described in detail
elsewhere (Schro¨der et al, 2009). Population-based trials with
identification of the target population from population registries
and randomisation before consent (Zelen, 1990) were carried out
in Finland, Italy, and Sweden. In the other countries involved in
the study (the Netherlands, Belgium, and Switzerland), a
volunteer-based approach was applied, with consent before
randomisation. The Spanish trial with only 2000 men was not
included owing to small size (only six deaths from prostate cancer
by 13 years). The only exclusion criterion was a previous diagnosis
of prostate cancer.
The men assigned to the screening arm were invited to
screening based on a serum PSA determination with a cut-off
value of 3.0 ngml 1 (in Finland, an ancillary test was provided for
men with PSA 3.0–3.9 ngml 1). Screen-positive men were
referred to prostate biopsy as a diagnostic examination. Diagnosis
was always based on pathological confirmation at histology. In
most centres, three screening rounds were provided (except two in
Belgium, five in the Netherlands, and up to 10 in Sweden) with an
interval of 4 years (2 years in Sweden).
Men in the control arm received normal care with no
intervention except follow-up for cancer incidence and mortality
obtained from cancer registries and population databases (and in
some countries surveys on screening and other PSA tests, quality of
life assessment, etc.). Surveys for men in the control arm and
analyses of data from laboratories carrying out PSA determinations
have indicated that contamination (opportunistic screening in the
control arm) was close to 20% in the first 4 years of the trial (Ciatto
et al, 2003; Otto et al, 2010).
Adjudication protocol and data used in this paper. According to
the ERSPC protocol, all deaths among men who had been
previously diagnosed with prostate cancer are evaluated by cause of
death adjudication committees, following a protocol that defines
both the categories of causes of death to be used (definite, probable,
and possible prostate cancer death, intervention-related death, as
well as definitely not prostate cancer), and the procedures for
assigning those causes of death (a predetermined decision
algorithm and a flow diagram; de Koning et al, 2003). The key
question to be addressed was: ‘Would this man have died at this
moment, if prostate cancer had not been present’? Medical records
for deceased men with prostate cancer diagnoses were obtained,
including relevant imaging (CT and/or X-rays). For adjudication
purposes, they were anonymised and de-identified in such a way
that any reference to PSA testing or the method by which cancer
had been detected were removed.
Death certificates were not provided and the official cause of
death was not disclosed. The assessment focused on determining
whether there was evidence of progressive prostate cancer,
indicated by the presence of metastases from prostate cancer. For
prostate cancer to be regarded as a definite cause of death, evidence
was required of metastatic prostate cancer with a progressive
disease course that had caused the patient’s death. Probable
prostate cancer death was defined as evidence of advanced and
progressive prostate cancer, but with some doubt about its role as
the final cause of death, for example, due to incomplete recording
of the disease course in the final stages of the patient’s life (de
Koning et al, 2003).
In each centre, a cause of death committee was formed to carry
out this adjudication. At least three members were involved, who
represented several medical specialties, commonly urology, pathol-
ogy, and internal medicine (de Koning et al, 2003). Each
adjudicator was provided with a copy of the records for the
deceased man and assigned the cause of death individually, and
independently of the other adjudicators; the study protocol
required three adjudicators to review each case. The cause of
death assignment was based on the extent of the disease (metastatic
vs local), disease progression and possible complications of
diagnostic measures and treatment. Disease extent and progression
were assessed on the basis of several criteria including clinical
picture, PSA (and other relevant laboratory tests), X-rays and/or
other relevant imaging results, histological findings, therapy, and
autopsy data (if any).
Intervention-related deaths were defined as those induced by
diagnostic or therapeutic interventions related to prostate cancer
(in either arm). It was included as a specific item in the study flow
chart. Early results on this topic have been published elsewhere
(de Koning et al, 2003).
If all adjudicators agreed on the role of prostate cancer in the
death, their unanimous decision was recorded as the cause of death
assigned by the committee. In contrast, any disagreements between
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adjudicators were resolved by discussion with the other committee
members at face-to-face meetings, to arrive at a consensus cause of
death. Any cases for which consensus could not be achieved were
referred to an international adjudication committee, formed by the
ERSPC with members from each of the local committees. It
convened to decide on difficult cases annually in the early phases of
the trial and less frequently afterwards with cases deliberated by
mail.
For this analysis, we obtained the original adjudication data for
individual committee members, which had been established and
recorded before the stage of committee discussion and case
resolution. In Finland, the committee was disbanded after a very
high degree of consistency had been shown between the consensus
adjudication of the committee and official causes of death
underlying cause, which initiated the train of events leading to
death from Statistics Finland (kappa 40.95; Ma¨kinen et al, 2008).
Therefore, the Finnish cause of death adjudication data were
available only for 1996–2003 (covering about one-third of the
prostate cancer deaths that have been reported in the most recent
mortality analysis for the study (Schro¨der et al, 2014). According to
the Finnish legislation, a copy of every death certificate has to be
sent to Statistics Finland. Death certificates are accepted as such or
modified according to the rules of WHO (ICD-10). Very high
agreement was reported between death certificates and cause of
death committee in Sweden (kappa 40.9; Godtman et al, 2011).
No restriction in terms of follow-up was used, which resulted in
larger numbers of deaths being included from Sweden and Belgium
(the centres with the longest follow-up available) compared with
the analyses previously reported that were truncated at 13 years
(Schro¨der et al, 2014) or earlier analyses based on shorter follow-
up (Schro¨der et al, 2009, 2012). Also, analyses reported in the
current paper were not restricted to the core age group (55–69
years at entry defined in the trial protocol as the primary target
population), unlike the primary analyses of prostate cancer
mortality (Schro¨der et al, 2009, 2012, 2014). The number of cases
included in the analysis corresponded to deaths accrued by 10.2
years of follow-up in the Netherlands, 16.8 years in Belgium, 16.7
years in Sweden, 7.4 years in Finland, and 10.4 years in
Switzerland. Substantially smaller numbers were included from
Finland (with no more adjudications after 2003), while there were
slightly fewer events from the Netherlands (inclusions up to 2012)
and comparable figures from Switzerland. For all these reasons, the
sample sizes used in the current analyses can be either greater or
less than those reported elsewhere for ERSPC, and the results may
differ somewhat from earlier findings due to lack of complete
overlap of the data.
Methods. All the analyses in this paper make comparisons
between deaths coded as ‘definite’ or ‘probably’ related to prostate
cancer, vs all other codes. We henceforth will refer to the former
group as ‘prostate cancer deaths’ and the latter as ‘non-prostate
cancer deaths’.
All the analyses were done separately for each centre, for several
reasons. First, there was an inherent interest in the centre-specific
results in terms of the adjudication process, and also the screening
effect may differ due to differences in populations or variation in
screening protocols. Second, we wished to avoid an assumption
that adjudication accuracy did not vary between countries. Third,
the data were inherently nested by centre, because the same group
of adjudicators evaluated all deaths within a centre.
We first performed descriptive analyses and cross-tabulations to
assess the available sample sizes by centre, and the amount of
available data by adjudicator within countries. One Dutch
adjudicator was excluded due to small number of cases (n¼ 16,
2%) evaluated. Empirical estimates of the odds ratios between the
study arm and the proportion of prostate cancer deaths were
calculated for the national consensus data for each centre.
Agreement between adjudicators was summarised using the kappa
statistic (Fleiss et al, 1981), with coefficients 0.4–0.6 regarded as
indicating moderate agreement, 0.6–0.8 as substantial and40.8 as
almost perfect agreement (Landis and Koch, 1977). McNemar’s
test was used to evaluate the tendency of one observer to
significantly over- or under-estimate the rate of prostate cancer
death, relative to another observer. Both these methods were used
for all possible pairs of adjudicators.
A series of latent class models (LCMs) were developed, to
estimate several parameters of interest. The models recognise that
there is no perfect (gold standard) method available to determine
the true classification of cause of death (prostate cancer vs other).
We formulate the probabilities that correspond to a given set of
observed adjudication results for a man, conditional on each
assumed value for the true (but unknown) cause of death being
correct. These probabilities are then weighted according to the
corresponding probabilities of each true cause of death; these latter
probabilities are also estimated, and they represent the prevalence
of each (true) cause of death in the sample (Walter and Franco,
2008; Walter et al, 2013).
In total, these probability elements provide the statistical
likelihood function for the entire dataset. Numerical iteration then
yields the maximum-likelihood estimators of the model para-
meters. In the particular analyses carried out here, the parameters
of interest are: the true prevalence of prostate cancer death; the
accuracy of the adjudicators (in terms of their sensitivity and
specificity); and the association (summarised by an odds ratio) of
the proportions of prostate cancer death with the study arm
(screened vs control).
There are three main models which were applied to the data
from each centre. Each model is defined by the set of terms on
which the estimated conditional probability of a particular set of
adjudication outcomes is based. Model 1 includes a set of terms
(X, T|X, A|X, B|X, C|X). The term X represents the true (but
unknown) cause of death of a man in the study, and its coefficient
indicates the true prevalence of prostate cancer deaths in the entire
sample. Terms such as A|X reflect the probability of an adjudicator
A recording a particular cause of death opinion, given the true
cause of death (X), and similarly for the other adjudicators B, C,y.
By conditioning on each of the possible true states X, we may
derive the sensitivity and specificity of each of the adjudicators.
The term T|X describes the association between the risk of prostate
cancer death and the study arm.
Model 2 is the same as model 1 except that constraints A|X¼
B|X¼C|X are added, implying that the adjudicators have equal
sensitivity and equal specificity. Model 3 includes terms (X, T|X,
A|XT, B|XT, C|XTy), with the latter terms implying that the
accuracy of the adjudicators (in terms of sensitivity and specificity)
may depend on the study arm, as well as on the true cause of death.
Likelihood ratio statistics and the Akaike Information criterion
(AIC) were used to compare models (Kleinbaum et al, 2007).
Comparisons between models 1 and 2 can reveal if there is a
statistically significant improvement of the model fit to the data by
allowing observer accuracy to vary. Comparisons between models
2 and 3 can indicate if there is a significant improvement in model
fit if observer accuracy is allowed to vary by study arm. If model 3
is found to fit significantly better to the data than model 2,
indicating an interaction of accuracy by arm, it would be evidence
of possible bias in the adjudication process. This could occur, for
instance, if adjudicators become unblinded, for example, due to
observing features that are more typically found in screen-detected
prostate cancers (local, small volume, well-differentiated, low PSA
at diagnosis), compared with cases in the control arm.
Comparisons of models 2 and 3 were made under the constraint
that observer accuracy did not vary. This was done partly because
the empirical results comparing models 1 and 2 showed only
limited evidence of observer heterogeneity, and also because the
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available sample sizes did not permit the stable fitting of models
where accuracy depended on both the particular observer and the
study arm.
As a final step in our analysis, we evaluated whether the
apparent error rates for our adjudicators could have affected
the main result of the study, specifically the odds ratio of prostate
cancer death by arm based on adjudication. For the sake of
comparability, we made that assessment using the same metho-
dology for each country. We began with the conventional odds
ratio calculated empirically from the cross-tabulation of study arm
and the adjudication consensus result. Second, we used the
estimated FPR and FNR from model 2 to adjust the proportions of
prostate cancer deaths in each study arm for adjudicator
inaccuracy (see Supplementary Material for details of this
calculation); a corrected odds ratio was then obtained from these
adjusted proportions. This approach assumes that the same level of
adjudicator accuracy pertains to both study arms. Next, we carried
out a similar calculation, but used FPR and FNR from model 3,
which permits adjudicator accuracy to differ between study arms.
Finally, an odds ratio can be obtained directly from the
association of the latent variable and study arm within a latent class
model. We elected to use model 2 for this purpose, because with
the exception of Sweden and Switzerland (with its smaller sample
size and less reliable model fit), there was no strong evidence of
differential accuracy by study arm, and we wished to retain the
same approach for all the countries.
RESULTS
Table 1 shows the sample sizes for each country, and the number
of cases evaluated by each adjudicator. The available sample size
was considerably smaller in Switzerland and Italy, compared with
elsewhere. Also shown are the number of prostate cancer deaths,
according to the national consensus, which ranged between 20%
and 43% of the total deaths adjudicated. The majority of
adjudicators had seen at least 95% of the available cases in their
countries. Sweden and Finland used only three adjudicators who
each evaluated all the cases (Finland) or almost all (Sweden). The
Netherlands had five adjudicators – two had seen 95% or more of
their cases, two others had each assessed approximately half of the
cases, and one who had seen only 2% of the sample; the last
adjudicator was dropped from our analysis. In Belgium and
Switzerland, there were four adjudicators, who had either seen all
the cases or approximately half of them. The Swiss cases were
afterwards re-evaluated by the chair of the international cause of
death committee (HJdK), but these results were not included in the
analysis.
In Italy, there were five adjudicators who had apparently each
seen all the cases; however, further analysis revealed absolutely no
variation in the cause of death assignments, with all the
adjudicators showing identical results for each case. This suggested
that the data were, in fact, likely composed of consensus decisions
after committee discussion, rather than original assignments by
individual adjudicators. This could not be verified because the local
committee chair had died. Therefore, no meaningful analysis was
possible, and we henceforth omit Italy from our report.
Table 2 shows the pairwise agreement (kappa values and their
standard errors) between adjudicators, by study arm and overall,
for each country. Also shown for each adjudicator pair is
McNemar’s test for asymmetry.
In the Netherlands, Belgium, Sweden, and Finland, all
adjudicator pairs had kappa statistics in the range 0.85–0.95 or
even higher, showing excellent agreement. There were only small
differences in agreement levels between study arms, and thus there
was no trend that might suggest differential reliability of
adjudication between the screening or control arms. As a corollary,
the overall agreement was similar to the arm-specific kappa value.
In Switzerland, with its much smaller sample size (particularly
for adjudicators who only saw a fraction of the total available
cases), the kappa values were less precisely estimated, and they
ranged from 0.31 to 0.93. There was some variability in reliability
between study arms, but this was not systematically in one
direction or the other. The overall kappa values were intermediate
between the study-specific values and ranged from 0.57 to 0.93,
indicating moderate to excellent agreement.
McNemar’s test for asymmetry was rarely statistically significant
(6 out of 66 tests at the 5% a-level), which is reasonably close to
what would be expected by chance, but we do acknowledge that the
symmetry tests are not independent of one another within centres.
Further detailed examination of the data summarised in Table 2
did not identify any adjudicators that were clearly in disagreement
with their peers more frequently. These results indicate that there
was no strong tendency for adjudicators to have different
thresholds for declaring prostate cancer deaths.
Table 3 shows the estimates of false positive and false negative
rates for each adjudicator, obtained from latent class model 1. Most
of these error rates were relatively small, typically less than 5%, but
there were a few exceptions where one rate or the other was
somewhat larger. Note that several estimated error rates were zero
(one each for Netherlands and Belgium, and two – for the same
adjudicator – for Switzerland); this may imply that the maximum-
likelihood solution for the model parameters may be somewhat less
reliable, being on a boundary of the admissible parameter space.
Also shown in Table 3 are the overall error rate estimates,
computed from model 2. Again, these values were quite modest,
but we note a tendency for the FNR to be higher than the FPR for
each country. Finally, Table 3 shows estimated error rates by study
arm, as given by model 3. There are typically no major differences
between study arms. Switzerland had lower FPR in the screening
arm, and lower FNR in the control arm, but these parameter
estimates were based on smaller sample sizes, and hence were
relatively imprecise; this was also the only analysis where a zero





1 2 3 4 5
Netherlands 697 162 (23%) 659 (95%) 284 (41%) 689 (99%) 400 (57%) 16 (2%)
Belgium 368 72 (20%) 368 (100%) 233 (63%) 367 (100%) 367 (100%) –
Sweden 418 168 (40%) 418 (100%) 412 (99%) 415 (99%) – –
Finland 435 168 (39%) 435 (100%) 435 (100%) 435 (100%) – –
Italy 51 22 (43%) 51 (100%) 51 (100%) 51 (100%) 51 (100%) 51 (100%)
Switzerland 87 32 (37%) 51 (59%) 87 (100%) 87 (100%) 36 (41%) –
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estimated error rate occurred. Standard errors for FNR and FPR
were typically in the range 0.5% to 1.5% with model 2, and slightly
higher for the smaller sample size in Switzerland. The standard
errors were somewhat higher from model 3 with its greater number
of parameters from the same amount of data.
The results of likelihood ratio tests to evaluate the heterogeneity
of adjudicator accuracy are shown in Table 4. In the left-hand
panel are shown the tests based on comparisons of latent class
models 1 and 2, which differ only with respect to the constraint
defining all adjudicators (within countries) to have the same error
rates: this constraint is absent from model 1, but applies in model
2, and hence their comparison indicates the potential improvement
in fit of the data by allowing adjudicators to vary in their accuracy.
Significant or borderline significant heterogeneity was found in all
the countries except Belgium, but the absolute estimates of error
rates were typically quite low. Also, note that the fits of model 1 in
the Netherlands and Switzerland were unstable, partly because
some boundary solutions were encountered (zero estimated error
rates for one or more observers), and partly (in the case of
Switzerland) because of small sample sizes; this means that the
P-values provided from their likelihood ratio tests may be only
approximately valid.
The right-hand panel of Table 4 summarises comparisons
between model 2 and 3. These models differ with respect to either
allowing adjudication accuracy to differ between the screening and
control study arms (model 3) or not (model 2). Here Sweden and
Switzerland had significant likelihood ratio tests, which is consistent
with the patterns of error rates seen in Table 3, but note that model 3
for Switzerland again involved a zero estimated error rate. However,
the Netherlands, Belgium, and Finland, all showed no evidence of
differential accuracy between the study arms. The AIC statistic, as an
alternative to the likelihood ratio method, gave almost identical
conclusions for these model comparisons. (Minor exceptions
occurred when comparing models 1 and 2, for instance when the
LR test showed borderline significance (PE0.07) for Sweden, but the
AIC criterion showed evidence of observer heterogeneity). Further
details are not shown here.
Table 2. Pairwise agreement (kappa; standard error) between adjudicators, by country
Adjudicator pair
Country Study arm 1 2 3 4 5 6
Netherlands Screen 0.92 (0.04) 0.85* (0.03) 0.94 (0.03) 0.81 (0.05) 0.88* (0.04) –
Control 0.89 (0.05) 0.87 (0.04) 0.93 (0.04) 0.84 (0.05) 0.83 (0.05) –
Overall 0.91 (0.03) 0.87* (0.02) 0.94 (0.02) 0.84 (0.03) 0.86 (0.03) –
Belgium Screen 0.92 (0.05) 0.89 (0.04) 0.86 (0.06) 0.93 (0.04) 0.89 (0.06) 0.92 (0.04)
Control 0.89 (0.05) 0.89 (0.04) 0.92 (0.04) 0.91 (0.04) 0.97 (0.03) 0.95 (0.03)
Overall 0.91 (0.03) 0.89 (0.03) 0.89 (0.04) 0.92 (0.03) 0.93 (0.03) 0.93 (0.03)
Sweden Screen 0.95 (0.02) 0.93 (0.03) 0.97 (0.02) – – –
Control 0.94 (0.03) 0.89 (0.03) 0.90 (0.03) – – –
Overall 0.94 (0.02) 0.91 (0.02) 0.94 (0.02) – – –
Finland Screen 0.90 (0.03) 0.85 (0.04) 0.89 (0.04) – – –
Control 0.89 (0.03) 0.86* (0.03) 0.92* (0.03) – – –
Overall 0.89 (0.02) 0.86* (0.03) 0.91 (0.02) – – –
Switzerland Screen 0.81 (0.13) 0.69 (0.17) 0.73 (0.11) 0.92 (0.08) 0.83 (0.12)
Control 0.31 (0.17) 0.49* (0.14) 0.75 (0.12) 1.00 ( ) 1.00 ( )
Overall 0.57 (0.11) 0.60 (0.11) 0.74 (0.08) 0.93 (0.07) 0.86 (0.10)
*Po0.05 on McNemar symmetry test.
Table 3. Estimated false positive (FPR) and false negative (FNR) adjudication rates (%, s.e.) by adjudicator, overall, and by study
arm
Data source
Country Error rate Adj. #1 Adj. #2 Adj. #3 Adj. #4 Overall Screening arm Control arm
Netherlands FPR (%) 0.4 (0.3) 0.5 (0.6) 1.8 (0.7) 0.5 (0.5) 0.9 (0.3) 0.7 (0.3) 1.3 (0.7)
FNR (%) 10.4 (2.5) 0.0 (0.0) 3.5 (1.5) 10.0 (3.0) 7.0 (1.3) 7.4 (2.0) 6.4 (1.7)
Belgium FPR (%) 0.7 (0.6) 1.2 (0.8) 0.7 (0.5) 0.0 (0.0) 0.6 (0.3) 0.5 (0.3) 0.6 (0.4)
FNR (%) 4.5 (2.5) 5.9 (3.5) 7.4 (3.3) 6.0 (3.2) 6.0 (1.6) 7.7 (2.7) 4.7 (2.0)
Sweden FPR (%) 0.8 (0.6) 0.8 (0.6) 2.8 (1.1) – 1.5 (0.5) 2.2 (1.1) 1.7 (0.8)
FNR (%) 3.7 (1.5) 0.6 (0.7) 1.3 (0.9) – 1.9 (0.7) 0.6 (0.4) 3.1 (1.1)
Finland FPR (%) 1.9 (1.1) 1.2 (0.9) 6.2 (1.9) – 2.5 (0.6) 2.4 (0.8) 2.7 (0.9)
FNR (%) 4.9 (1.3) 1.5 (0.8) 1.2 (0.7) – 3.1 (0.9) 3.3 (1.4) 3.1 (1.1)
Switzerland FPR (%) 20.8 (7.7) 5.6 (3.4) 4.4 (3.1) 0.0 (0.0) 6.9 (2.4) 2.2 (1.6) 20.7 (5.5)
FNR (%) 6.2 (6.7) 5.9 (5.7) 10.4 (6.6) 0.0 (0.0) 7.5 (4.0) 10.7 (5.7) 0.0 (0.0)
Note: results for individual adjudicators (Adj) #1 to #4 are from model 1; the overall results are from model 2; the screening and control arm results are from model 3.
Table 4. Likelihood ratio test results for evaluating
heterogeneity in adjudication accuracy
Test of adjudicator
heterogeneity (latent class
models 1 vs 2)
Test of study arm
heterogeneity (latent class
models 2 vs 3)
Country LR statistic D.f. P LR statistic D.f. P
Netherlands 20.84 6 o0.01 0.8 2 0.67
Belgium 4.78 6 0.57 0.9 2 0.64
Sweden 8.54 4 0.07 6.24 2 0.04
Finland 15.62 4 o0.01 0.04 2 0.98
Switzerland 11.98 6 0.06 10.58 2 o0.01
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Table 5 shows the observed, corrected, and latent class model-
based odds ratios for prostate cancer death by arm, for each
country. The odds ratios obtained by the various methods were
generally very similar. The two odds ratio estimates corrected for
adjudicator inaccuracy reasonably approximate what was actually
observed empirically, with some deviations when using model 3 in
the smaller sample of Swiss data, and with a slightly smaller
screening effect in Belgium. The estimates obtained directly from
the LCM (last column of Table 5) show close agreement with the
empirical estimates in the Netherlands, Sweden, and Finland, a
slightly smaller screening effect in Belgium, and a slightly larger
effect in Switzerland. However, these discrepancies are relatively
small, and all the odds ratios are less than 1, which indicates a
reduction of prostate cancer deaths in the screening arm.
We elected not to calculate model-based estimates of the odds
ratios at the level of individual adjudicators (which would use
model 1 results), partly because of model instability in several cases
(Netherlands, Belgium, and Switzerland), partly because of limited
available data for some adjudicators, and partly because the
original empirical study result is based on the adjudication
consensus rather than individual opinions.
DISCUSSION
The analysis revealed some variation in adjudicated outcomes by
observer (as would be anticipated in all practical situations).
However, the pairwise agreement was generally very good, and
there was only limited evidence of asymmetry in accuracy between
adjudicators; hence disagreements between adjudicators typically
occurred in both directions of classifying a death as related to
prostate cancer or not. The latent class models showed some
evidence of observer heterogeneity in accuracy, but the data for
three countries led to boundary (zero) estimates of some model
parameters; when an error rate for an adjudicator is zero, it implies
that significance tests and standard errors for all the model
parameters may be somewhat less accurate than otherwise. Despite
this, there was no consistent evidence of differential accuracy by
trial arm. Hence we conclude that bias arising from adjudication
inaccuracy (because of potential loss of blinding, for example) was
unlikely. Using the latent class model results to generate alternative
estimates of the study odds ratios made little difference in
comparison with the empirical effect estimates.
The results obtained using this analytical approach are
qualitatively consistent with ‘standard analyses’ using full data
reported previously, though the data utilised are not completely
overlapping. The effect estimates here are larger, which is mainly
due to analysis relating frequency of prostate cancer deaths to
overall numbers of deaths, while in the previous analyses the
prostate cancer deaths have been related to population size or
person-years of follow-up. Here, fewer prostate cancer deaths are
included than in the previous analyses of 13 years of follow-up
(Schro¨der et al, 2014), mainly due to our restricted attention to
early deaths only in Finland, the largest centre, while the numbers
were comparable for most other centres. Note also that in contrast
to previous analyses of the ERSPC data, we only included definite
or probable prostate cancer deaths as events, while intervention-
related deaths were not included. There was only a small numbers
of cases in the latter group so they would have only a minimal
impact on the current results.
The aim of the current work was not, however, to obtain an
alternative estimate of the effect size (impact of screening on
prostate cancer mortality), but to examine the potential impact of
the adjudication of the cause of death on the primary outcome by
comparing the uncorrected and corrected estimates in this subset
of the ERSPC data. In principle, the potential artefactual influences
that could bias the ERSPC result and lead to an apparent screening
effect include differential misclassification of causes of death (e.g.,
lower sensitivity or higher specificity in the screening arm), and
more effective treatment provided for prostate cancer in the
screening arm. We have shown here that the first explanation can
be ruled out. This result is consistent with another secondary
analysis, using excess mortality as the outcome, which also
suggested that misclassification of causes of death would not affect
the overall result (Kranse et al, 2013; Van Leeuwen et al, 2013).
Other analyses related to treatment differences are on-going.
Some differences in screening effect between centres remained,
which may reflect variations in screening protocol such as
screening interval, or number of screening rounds, as well as
inherent differences in the study populations. In addition, the
extent of contamination, i.e., screening in the control arm, is likely
to dilute the screening effect and may contribute to differences
between centres. On the other hand, our results were similar for
centres with population-based and volunteer-based recruitment.
The cause of death adjudication in the ERSPC trial was similar
to that originally adopted in the PLCO trial, though in the latter,
the process was simplified subsequently (Miller et al, 2015). No
similar analysis has been conducted in the PLCO, however. In the
UK CaP trial, a comparable approach was used and an analysis
showed that the blinding regarding trial allocation of the cases was
retained during the cause of death review process (Williams et al,
2015). In the CaP trial (Turner et al, 2016), sensitivity and
specificity of committee adjudication was comparable to the Dutch
ERSPC data (Otto et al, 2010), but lower than that reported from
the Nordic countries (Ma¨kinen et al, 2008; Godtman et al, 2011).








adjudicator accuracy by study armc Directly from latent class modeld
Netherlands 0.342 0.35 0.337 0.328
Belgium 0.759 0.904 0.866 0.902
Sweden 0.355 0.381 0.395 0.368
Finland 0.52 0.575 0.568 0.556
Switzerland 0.625 0.5 0.259 0.437
aEstimated from cross-tabulation of adjudication consensus by study arm.
bEstimated proportions of prostate cancer deaths in each study arm were corrected using estimated false positive and false negative adjudication rates in LCM 2. Odds ratio is then calculated
from these corrected proportions.
cSimilar to approach (b), except that adjudicator accuracy was estimated from LCM 3.
dBased on LCM 2 estimates of the association of study arm with the latent variable (prostate cancer death).
BRITISH JOURNAL OF CANCER Prostate screening
146 www.bjcancer.com |DOI:10.1038/bjc.2016.378
In our adjudication, any reference to screening was deleted from
the medical records, as well as the immediate chain of events
leading to diagnosis. All this was done to maintain blinding of the
adjudicators with respect to which trial arm the man had been
randomised to. The findings that we report here support the notion
that blinding was maintained.
Our results are concordant with an analysis of four cancer
screening trials, in which use of committee reviews vs cause of
death data had only minor influence on the estimates of screening
effectiveness, though in one trial only the analysis based on
adjudicated causes gave a significant effect, but not that using death
certificates (Doria-Rose et al, 2010).
In summary, we can conclude that observer variation, while
demonstrably present, was unlikely to have had a strong influence
on the main study results. Hence, we conclude that the ERSPC
results are not attributable to biased or unreliable cause of death
adjudication, and one possible source of bias that could explain a
mortality reduction associated with prostate screening can be
effectively ruled out.
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